NYSE$PBH
Prestige Consumer Healthcare Inc · Q2 2026 earnings
Q2 2026 earnings · · Before market open · Investor relations
Briefing
Prestige Consumer Healthcare reported Q2 2026, revenue of $273.8M, net income of $42.2M.
For Q2 2026, Prestige Consumer Healthcare reported revenue of $273.8M, net income of $42.2M. Management discusses segment performance, capital allocation, and sector risks in the quarterly filing.
- Revenue $273.8M.
- Net income $42.2M.
- Prestige Consumer Healthcare MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Prestige Consumer · Revenue · Quarterly
$274M
Revenue by segment
Prestige Consumer · $286M total across 2 segments · Q2 2024
- North American OTC Healthcare$244M-3.0%85.4%
- International OTC Healthcare$41.9M+12.6%14.6%
Forward guidance
Consumer and financial services outlook focuses on volume, pricing, and productivity.
Tailwinds
- Brand and distribution strength.
- Cost actions.
- Capital allocation.
Headwinds
- Input costs and competition.
- Macro consumer spend.
- Regulatory changes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2026
+1.3%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+1.3%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+25.7%
Q4 2018
Best reaction
-14.3%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.5% | -7.4% | -4.9% | |
| Q3 2026 | -2.2% | -1.4% | +0.2% | |
| Q2 2026 | +2.2% | +1.3% | +1.7% | |
| Q4 2025 | +7.0% | +6.8% | +4.5% | |
| Q3 2025 | +14.8% | +13.0% | +17.0% | |
| Q2 2025 | +3.5% | +5.1% | +8.6% | |
| Q1 2025 | -2.4% | -0.9% | +9.5% | |
| Q4 2024 | -5.7% | -8.3% | -8.0% | |
| Q3 2024 | +9.2% | +5.8% | +17.2% | |
| Q2 2024 | +0.1% | +0.6% | -1.5% | |
| Q1 2024 | +2.2% | -2.5% | -11.4% | |
| Q4 2023 | -0.8% | -4.7% | -4.5% | |
| Q3 2023 | -7.9% | -8.3% | -8.9% | |
| Q2 2023 | +2.2% | +4.6% | +17.7% | |
| Q1 2023 | -0.3% | -3.9% | -15.2% | |
| Q4 2022 | -0.8% | +4.0% | +1.6% | |
| Q3 2022 | -0.2% | +2.2% | +1.1% | |
| Q2 2022 | +2.5% | +1.9% | -6.0% | |
| Q1 2022 | +10.5% | +12.3% | +8.1% | |
| Q4 2021 | +4.0% | +6.2% | +12.8% | |
| Q3 2021 | +3.2% | +5.5% | +6.3% | |
| Q2 2021 | -3.5% | +3.0% | +6.9% | |
| Q1 2021 | +2.7% | -1.9% | -5.2% | |
| Q4 2020 | +1.7% | +0.1% | +3.5% | |
| Q3 2020 | +10.7% | +5.7% | -8.3% | |
| Q2 2020 | +5.8% | +8.5% | +8.2% | |
| Q1 2020 | -3.1% | -5.6% | -7.9% | |
| Q4 2019 | +3.8% | +1.1% | +0.5% | |
| Q3 2019 | -2.9% | +2.8% | -4.1% | |
| Q2 2019 | +4.3% | +12.2% | +7.4% | |
| Q1 2019 | +3.5% | +5.3% | +9.3% | |
| Q4 2018 | +25.7% | +21.4% | +25.1% | |
| Q3 2018 | -14.3% | -10.9% | -15.3% | |
| Q2 2018 | -8.3% | -9.3% | -4.9% | |
| Q1 2018 | +1.6% | +0.7% | -2.4% | |
| Q4 2017 | -8.3% | -11.2% | -9.5% | |
| Q3 2017 | +5.8% | +4.9% | +7.8% | |
| Q2 2017 | -0.5% | +0.8% | +0.6% | |
| Q1 2017 | -1.6% | -5.0% | -8.1% | |
| Q4 2016 | -0.7% | — | — | |
| Q3 2016 | +7.6% | — | — | |
| Q2 2016 | -1.7% | — | — | |
| Q1 2016 | -0.2% | — | — | |
| Q4 2015 | +3.3% | — | — | |
| Q3 2015 | +12.5% | — | — | |
| Q2 2015 | -7.6% | — | — | |
| Q1 2015 | +10.1% | — | — | |
| Q4 2014 | +0.2% | — | — | |
| Q3 2014 | -5.5% | — | — | |
| Q2 2014 | +13.2% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | -0.4% | — | — | |
| Q3 2013 | +5.8% | — | — | |
| Q2 2013 | +19.9% | — | — | |
| Q1 2013 | +4.1% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q4 2012 | +1.4% | — | — | |
| Q3 2012 | -1.0% | — | — | |
| Q3 2011 | -1.0% | — | — | |
| Q2 2011 | -4.8% | — | — | |
| Q2 2012 | -4.8% | — | — | |
| Q4 2011 | -13.0% | — | — | |
| Q1 2011 | -13.0% | — | — | |
| Q1 2012 | -13.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro